眼睑恶性肿瘤靶向及免疫治疗进展  

Progress in targeted therapy and immunotherapy for eyelid malignancies

作　　者：张露尹 姜利斌[1] Zhang Luyin;Jiang Libin(Beijing Tongren Eye Center,Beijing Tongren Hospital,Capital Medical University,Beijing Key Laboratory of Ophthalmology and Visual Science,Beijing 100730,China)

机构地区：[1]首都医科大学附属北京同仁医院、北京同仁眼科中心、眼科学与视觉科学北京市重点实验室,北京100730

出　　处：《国际眼科纵览》2023年第5期436-444,共9页International Review of Ophthalmology

基　　金：北京市自然科学基金(7222028);首都卫生发展科研专项基金(2020-2-1082)

摘　　要：眼睑恶性肿瘤是常见的眼附属器恶性肿瘤,除能影响患者的视力和外观外,还会对患者生命产生极大威胁。近年来,基于Hedgehog通路、表皮生长因子受体(epidermal growth factor receptor,EGFR)和鼠类肉瘤滤过性病毒致癌基因同源体B1(v-Raf murine sarcoma viral oncogene homolog B1,BRAF)介导信号通路以及免疫检查点抑制剂的研究,已有部分靶向药物和免疫治疗药物显示出对某些眼睑恶性肿瘤,如基底细胞癌、鳞状细胞癌、恶性黑色素瘤和Merkel细胞癌的一定疗效。靶向治疗和免疫治疗为手术切除后复发、全身药物治疗后进展、局部晚期或转移的眼睑恶性肿瘤患者提供了更多选择。与单药治疗相比,联合治疗缓解率更高,患者生存期更长。未来,更多的通路下游作用靶点的发现以及更优的联合方案的使用,给眼睑恶性肿瘤患者带来更多治疗上的选择。Eyelid malignancies are common ocular adnexal malignancies,which can not only affect the patient's vision and appearance,but also have a great threat to the patient's life.In recent years,based on the studies of the Hedgehog pathway,epidermal growth factor receptor(EGFR)and v-Raf murine sarcoma viral oncogene homolog B1(BRAF)mediated pathways and the immune checkpoint pathway,some targeted agents have shown certain efficacy and safety against eyelid malignancies,such as basal cell carcinoma,cutaneous squamous cell carcinoma,malignant melanoma,and Merkel cell carcinoma.Targeted therapy and immunotherapy provide additional options for patients with eyelid malignancies that recur after surgical resection,progress after systemic therapy,locally advanced or metastatic.Combined therapies have a higher response rate and longer survival than monotherapy.In the future,with the discovery of more downstream targets and better combined therapies,more treatment options will be available for eyelid malignancies.

关 键 词：眼睑恶性肿瘤 分子靶向治疗 免疫治疗 

分 类 号：R739.7[医药卫生—肿瘤]